The global lung cancer surgery market is estimated to be USD 48.15 billion by 2029 from USD 34.46 billion in 2024, growing at a CAGR of 6.92% during the forecast period.
Lung cancer, sometimes called lung carcinoma, is a malignant tumor marked by uncontrolled cell growth in lung tissues. People who use a lot of nicotine or who smoke are more likely to get lung cancer. Lung cancer risk rises with time and with the number of cigarettes smoked by an individual. Biopsy, performed under bronchoscopy or CT guidance, includes lung cancer treatment. The surgical removal of cancerous tissue from the lungs is known as lung cancer surgery. Small and non-small cell lung cancer are the two most common forms. The type of surgery is determined by the tumor’s location and size within the lung. Then, the tumor is removed using a surgical technique or process. After surgery, some patients have discomfort and problems, although these are generally managed by medicine.
According to the State of Lung Cancer 2021 Report by the American Lung Association, one person is diagnosed with lung cancer in the United States every 2.5 minutes, and an estimated 382 people die from lung cancer each day. Recently, the awareness levels of lung cancer have improved, and an increase in the survival rate of lung cancer among Americans has been noticed. Increased risk factors among expanding tobacco smokers and YOY growth in the aging population are contributing to the growth of the lung cancer surgery market. Furthermore, technical improvements in cancer therapy, a growing trend toward early cancer detection and treatment, and favorable reimbursement policies are expected to aid the market growth in the coming years. Furthermore, the growing air pollution levels are expected to promote the incidence of lung cancer, which is further expected to favor the lung cancer surgery market growth. According to Cancer Research UK, one out of ten lung cancer cases are due to outdoor air pollution. The growing awareness among people regarding the risks associated with cancer, available treatment options, and reimbursement policies are expected to showcase a favorable impact on the market’s growth rate.
In addition, factors such as the introduction of advanced healthcare infrastructure, YOY growth in the number of smokers, and reduction in the time required for lung cancer surgeries using new advanced technologies are influencing the market growth positively. Furthermore, the growing adoption of technological advancements in treatment procedures and increased government funding to conduct R&D in the development of new drugs and treatment procedures are expected to boost the lung cancer surgery market growth. Furthermore, the adoption of automation and robotic surgeries for surgical procedures is gaining popularity and acceptability among healthcare professionals and is expected to impact the lung cancer surgery market positively. Robotic operations are minimally intrusive, which makes them more comfortable for patients. Emerging countries such as Brazil, India, and China have significant opportunities for the market players in the lung cancer surgery market. Furthermore, growing disposable income has enabled the patient population in existing countries to opt for technologically advanced material services and solutions. This attribute is regarded as driving the demand for advanced medical devices and the spread of surgery products.
Lack of awareness of the availability of surgery options to treat lung cancer, limited quality of being easy to obtain novel approaches, post-surgery complications of lung cancer surgeries, and high costs are some factors hampering the market growth. To overcome the challenges, a few companies offer a growing portfolio of specially focused solutions designed to improve the health and quality of people’s lives worldwide. This portfolio is known for new devices that simplify complex procedures. In addition, the global lung cancer surgery market is anticipated to be restrained by a shortage of skilled healthcare professionals for lung cancer treatment and a lack of adequate healthcare infrastructure in emerging nations throughout the forecast period.
REPORT METRIC |
DETAILS |
Market Size Available |
2023 to 2029 |
Base Year |
2023 |
Forecast Period |
2024 to 2029 |
Segments Analysed |
By Procedure, Device & Region |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis; DROC; PESTLE Analysis; Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
Regions Analysed |
North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa |
Key Market Players |
Ethicon US LLC, Intuitive Surgical Inc., Olympus Corporation, Accuray Inc., AngioDynamics Inc., Teleflex Inc., KARL STORZ GmbH, Ackermann Instrumente GmbH, Scanlan International Inc. and Trokamed GmbH. |
The segmentectomy segment is predicted to account for the largest share of the global lung cancer surgery market during the forecast period. Non-small cell lung cancer can be treated with a segmentectomy, a frequent surgical procedure (NSCLC). If the patient already has a severely depleted lung reserve, it is usually preferred over lobectomy. Although lung segmentectomy has long been famous for the excision of supporting lesions and non-malignant masses, it is most often indicated for lung cancer, which is still in its early stages. This procedure has gained popularity due to better results, less discomfort, and faster recovery than standard surgical techniques. In addition, the segmentectomy treatment has a high success rate for eliminating localized tumors and cancers, with excellent survival rates and the ability to retain organ functioning to some extent. These benefits are expected to drive market expansion.
The minimally invasive surgeries segment is anticipated to grow aggressively during the forecast period. The increased use of minimally invasive methods, technological developments, reimbursement regulations, and the expanding trend of robotic operations are all factors driving this segment's rise during the forecast period.
The surgical segment held the largest share of the lung cancer surgery market in 2023. The segment's growth is primarily driven by the growing number of lung cancer cases, increased support from various governments and financing, and increased use of surgical techniques for lung cancer therapy.
North America dominated the market in 2023, and the domination of the region is expected to continue throughout the forecast period owing to an increase in the aging population, the rising incidence rate of lung cancer, and the availability of favorable reimbursement policies for lung cancer surgery in the North American countries. In addition, the advanced healthcare infrastructure that supports technologically advanced surgeries, such as robotic surgery, is likely to bolster regional market growth. Furthermore, technological advancements in surgical methods are projected to drive the growth of this region's lung cancer surgery market. People with lung cancer are growing considerably in the countries of North America. Non-small cell lung cancer is cured in tens of thousands of patients in the United States annually. Lung cancer is a disease that primarily affects the elderly. This reflects the high prevalence of lung cancer in this nation, which has expanded the market due to the strong demand for cancer treatment.
Asia ranks as the fastest-growing regional market in the global market for the upcoming years owing to the growing population, increasing incidence of lung cancer, and increasing number of campaigns to promote awareness around lung cancer. Owing to the strict regulatory policies and low competition, the Asia-Pacific region is anticipated to offer lucrative growth opportunities to market participants during the forecast period. However, high. The high costs associated with robotic surgeries can be problematic for developing Asia Pacific countries such as India and China. On the other hand, due to the growing developments in the healthcare infrastructure, rising awareness among patients, and increasing acceptance of technologically developed robotic operations in Japan and other emerging economies such as India and China, the Asia Pacific market is projected to be the most lucrative market among all regions in the worldwide market.
Europe is predicted to showcase a steady CAGR during the forecast period. According to an article published by the European Lung White Book, lung cancer has an estimated 20% contribution to the total number of deaths resulting from cancers in Europe. Furthermore, the growing patient count who has lung cancer and the increasing adoption of technological advancements in performing lung cancer surgeries are anticipated to result in regional market growth.
Latin America is expected to witness a steady pace during the forecast period. The MEA market held a moderate share in the global market and is predicted to grow at a considerable CAGR in the coming days.
Some of the notable companies leading the global lung cancer surgery market profiled in this report are Ethicon US LLC, Intuitive Surgical Inc., Olympus Corporation, Accuray Inc., AngioDynamics Inc., Teleflex Inc., KARL STORZ GmbH, Ackermann Instrumente GmbH, Scanlan International Inc. and Trokamed GmbH.
By Procedure
By Device
By Region
Frequently Asked Questions
The global lung cancer surgery market size was valued at USD 28.2 billion in 2021.
The global lung cancer surgery market is expected to grow at a CAGR of 6.92% from 2022 to 2027.
Fewer awareness levels regarding the surgeries options to cure lung cancer and high costs associated with the surgeries are showcasing negative impact on the growth of the lung cancer surgery market.
Ethicon US LLC, Intuitive Surgical Inc., Olympus Corporation, Accuray Inc., AngioDynamics Inc., Teleflex Inc., KARL STORZ GmbH, Ackermann Instrumente GmbH, Scanlan International Inc. and Trokamed GmbH are some of the key players in the lung cancer surgery market.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region